Decreased tumor surveillance in perforin-deficient mice

Journal of Experimental Medicine

Volumn 184, Issue 5, 1996, Pages 1781-1790

  Van Den Broek, Maries F ^a,d   Kägi, David ^e   Ossendorp, Ferry ^c   Toes, René ^c   Vamvakas, Spiros ^b   Lutz, Werner K ^b   Melief, Cornelis J M ^c   Zinkernagel, Rolf M ^a   Hengartner, Hans ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; CD8 ANTIGEN; DIMETHYLBENZ[A]ANTHRACENE; FAS ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PERFORIN; PHORBOL 13 ACETATE 12 MYRISTATE; TUMOR ANTIGEN;

ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER CONTROL; CONTROLLED STUDY; CYTOTOXICITY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR;

EID: 0029804782     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.184.5.1781     Document Type: Article

References (48)

1. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
2. Melief, C.J. 1992. Tumour eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58:143-175.
3. van Pel, A., P. van der Bruggen, P.C. Coulie, V.G. Brichard, B. Lethe, B. van den Eynde, C. Uyttenhove, J.C. Renauld, and T. Boon. 1995. Genes coding for tumour antigens recognized by cytolytic T lymphocytes. Immunol. Rev. 145:229-250.
4. Chen, L., S. Ashe, W.A. Brady, I. Hellström, K.E. Hellström, J.A. Ledbetter, P. McGowan, and P.S. Lindsley. 1992. Costimulation of antitumor immunity by the counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093-1102.
5. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol. 153: 421-428.
6. Hellström, K.E., I. Hellström, and L. Chen. 1995. Can costimulated tumour immunity be therapeutically efficacious? Immunol. Rev. 145:121-145.
7. Linsley, P.S., and J.A. Ledbetter. 1995. The role of CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11:191-219.
8. Schrier, P.I., R. Bernards, T.M.J. Vaessen, A. Houweling, and A.J. van der Eb. 1983. Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature (Lond.). 305:771-775.
9. Zijlstra, M., and C.J.M. Melief. 1983. Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature (Lond.). 305:776-779.
10. Smith, M.E.F., S.G.E. Marsh, J.G. Bodmer, K. Gelsthorpe, and W.F. Bodmer. 1989. Loss of HLA-A,B,C allele products and lymphocyte function-associated antigen 3 in colorectal neoplasia. Proc. Natl. Acad. Sci. USA. 86:5557-5561.
11. Uyttenhove, C., J. Maryanski, and T. Boon. 1983. Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than to immunosuppression. J. Exp. Med. 157:1040-1052.
12. Karre, K., H.G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immunedefence strategy. Nature (Lond.). 319:675-678.
13. van den Brock, M.F., D. Kägi, R.M. Zinkernagel, and H. Hengartner. 1995. Perform dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25:3514-3516.
14. Kägi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K.J. Olsen, E.R. Podack, R.M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (Lond.). 369:31-37.
15. Garner, R., C.D. Helgason, E.A. Atkinson, M.J. Pinkoski, H.L. Ostergaard, O. Sorensen, A. Fu, P.H. Lapchak, A. Rabinovitch, J.E. McElhaney et al. 1994. Characterization of a granule-independent lytic mechanism used by CTL hybridomas. J. Immunol. 153:5413-5421.
16. Berke, G. 1993. The functions and mechanisms of action of cytolytic lymphocytes, In Fundamental Immunology. W.E. Paul, editor. Raven Press Ltd., New York. 965-1014.
17. Kägi, D., B. Ledermann, K. Bürki, R.M. Zinkernagel, and H. Hengartner. 1995. Lymphocyte-mediated cytotoxicity in vitro and in vivo: mechanisms and significance. Immunol. Rev. 146:95-116.
18. Walsh, C.M., M. Matloubian, C.-C. Liu, R. Ueda, C.G. Kurahara, J.L. Christensen, M.T.F. Huang, J.D.E. Young, R. Ahmed, and W.R. Clark. 1994. Immune function in mice lacking the perform gene. Proc. Natl. Acad. Sci. USA. 91: 10854-10858.
19. Kojima, H., N. Shinohara, S. Hanaoka, Y. Someya-Shirota, Y. Takagaki, H. Ohno, T. Saito, T. Katayama, H. Yagita, K. Okumura et al. 1994. Two distinct pathways of specific killing revealed by perform mutant cytotoxic T lymphocytes. Immunity. 1:357-364.
20. Kägi, D., F. Vignaux, B. Ledermann, K. Bürki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell mediated cytotoxicity. Science (Wash. DC). 265:528-530.
21. Lowin, B., M. Hahne, C. Mattmann, and J. Tschopp. 1994. Cytolytic T cell cytotoxicity is mediated through pertorin and Fas lytic pathways. Nature (Lond.). 370:650-652.
22. 2+-independent T cell mediated cytotoxicity. J. Exp. Med. 177:195-200.
23. + T cell-mediated protection against an intracellular bacterium by perforin. Eur. J. Immunol. 24: 3068-3072.
24. Kägi, D., B. Odermatt, P.S. Ohashi, R.M. Zinkernagel, and H. Hengartner. 1996. Development of insulitis without diabetes in transgenic mice lacking perforin-dependent cytotoxicity. J. Exp. Med. 183:2143-2152.
25. Kägi, P., P. Seiler, J. Pavlovic, B. Ledermann, K. Bürki, R.M. Zinkernagel, and H. Hengartner. 1995. The roles of perforin- and Fas-dependent cytotoxicity in protection against cytpathic and noncytopathic viruses. Eur. J. Immunol. 25: 3256-3262.
26. Schulz, M., H.J. Schuurman, J. Joergensen, C. Steiner, T. Merloo, O. Kägi, H. Hengartner, R.M. Zinkernagel, M. Schreier, K. Bürki, and B. Ledermann. 1995. Acute rejection of vascular heart allografts by perforin deficient mice. Eur. J. Immunol. 25:474-480.
27. Walsh, C.M., F. Hayashi, D. Saffran, S. Ju, G. Berke, and W.R. Clark. 1996. Cell-mediated cytotoxicity results from, but may not be critical for, primary allograft rejection. J. Immunol. 156:1436-1441.
28. Braun, M.Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional Fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal graft-versus-host disease. J. Exp. Med. 183:657-661.
29. Fung-Leung, W.P., M.W. Schilham, A. Rahemtulla, T.M. Kündig, M. Vollenweider, J. Potter, W. van Ewijk, and T.W. Mak. 1992. CD8 is needed for development of cytotoxic T cells but not for helper T cells. Cell. 65:443-451.
30. Shinkai, Y., G. Rathbun, K.P. Lam, E.M. Oltz, V. Stewart, M. Mendelsohn, J. Charron, M. Datta, F. Young, A.M. Stall, and F.W. Alt. 1992. RAG-2 deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell. 68:855-864.
31. Doherty, P.C., W.E. Biddison, J.R. Bennink, and B.B. Knowles. 1978. Cytotoxic T cell responses in mice infected with influenza and vaccinia virus vary in magnitude with H-2 genotype. J. Exp. Med. 148:534-543.
32. Puddington, L., M.J. Bevan, and L. Lefrançois. 1986. N protein is the predominant antigen recognized by vesicular stomatitis virus-specific cytotoxic T cells. J. Virol. 60:708-716.
33. Toes, R.E.M., R. Offringa, R.J.J. Blom, R.M.P. Brandt, A.J. van der Eb, C.J.M. Melief, and W.J.M. Kast. 1995. An adenovirus type 5 early region 1B CTL epitope mediating tumor eradication by CTL clones is downmodulated by an activated ras oncogene. J. Immunol. 154:3396-3405.
34. Cobbold, S.P., A. Jayasuriya, A. Nasch, T.D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.). 312: 548-552.
35. Sheenan, K.C.F., N.H. Ruddle, and R.D. Schreiber. 1989. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors. J. Immunol. 142:3884-3893.
36. Mackett, M., T. Yilma, J.K. Rose, and B. Moss. 1985. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science (Wash. DC). 227:433-435.
37. Ehl, S., U. Hoffmann-Rohrer, S. Nagata, H. Hengartner, and R.M. Zinkernagel. 1996. Different susceptibility of cytotoxic T cells to CD97 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo. J. Immunol. 156: 2357-2360.
38. Lehmann-Grube, F. 1971. Lymphocytic choriomeningitis virus. Virol. Monogr. 10:1-11.
39. Stukart, M.J., A. Vos, and C.J.M. Melief. 1981. Cytotoxic T cell response against lymphoblasts infected with Moloney (Abelson) murine leukemia virus. Methodological aspects and H-2 requirements. Eur. J. Immunol. 11:251-257.
40. Pircher, H.P., D. Moskophidis, U. Rohrer, K. Bürki, H. Hengartner, and R.M. Zinkernagel. 1990. Viral escape by selection of cytotoxic T cell resistant variants in vivo. Nature (Lond.). 346:629-633.
41. Fischer, W.H., P.E. Beland, and W.K. Lutz. 1993. DNA adducts, cell proliferation and papilloma latency time in mouse skin after repeated dermal application of DMBA and TPA. Carcinogenesis. 14:1285-1288.
42. Kündig, T.M., M.F. Bachmann, L. Lefrançois, L. Puddington, H. Hengartner, and R. Zinkernagel. 1993. Nonimmunogenic tumor cells may efficiently restimulate tumor antigen-specific cytotoxic T cells. J. Immunol. 150:4450-4456.
43. Owen, S.L., R. Radinsky, E. Kruzel, K. Berry, and S. Yonehara. 1994. Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive for biological responsiveness. Cancer Res. 54:1580-1586.
44. Prehn, R.T., and J.M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18: 769-778.
45. Bubbers, E.J., and F. Lilly. 1977. Selective incorporation of H-2 antigenic determinants into Friend virus particles. Nature (Lond.). 266:458-459.
46. Bubbers, E.J., S. Chen, and F. Lilly. 1978. Nonrandom inclusion of H-2K and H-2D antigens in Friend virus particles from mice of various strains. J. Exp. Med. 147:340-351.
47. Levy, J.P., and J.C. Leclerc. 1977. The murin sarcoma virus-induced tumor: exception or general model in tumor immunology? Adv. Cancer Res. 24:1-66.
48. b mutants. J. Immunol. 128:1360-1364.